immatics biotechnologies GmbH (IMTXW) - Total Assets
Based on the latest financial reports, immatics biotechnologies GmbH (IMTXW) holds total assets worth $641.69 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IMTXW operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
immatics biotechnologies GmbH - Total Assets Trend (2018–2024)
This chart illustrates how immatics biotechnologies GmbH's total assets have evolved over time, based on quarterly financial data. See what is immatics biotechnologies GmbH's book value for net asset value and shareholders' equity analysis.
immatics biotechnologies GmbH - Asset Composition Analysis
Current Asset Composition (December 2024)
immatics biotechnologies GmbH's total assets of $641.69 Million consist of 90.4% current assets and 9.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.0% |
| Accounts Receivable | $6.75 Million | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.63 Million | 0.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how immatics biotechnologies GmbH's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see immatics biotechnologies GmbH stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: immatics biotechnologies GmbH's current assets represent 90.4% of total assets in 2024, an increase from 90.2% in 2018.
- Cash Position: Cash and equivalents constituted 34.0% of total assets in 2024, down from 64.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
immatics biotechnologies GmbH Competitors by Total Assets
Key competitors of immatics biotechnologies GmbH based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
immatics biotechnologies GmbH - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.28 | 3.95 | 1.05 |
| Quick Ratio | 10.28 | 3.95 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $517.79 Million | $439.70 Million | $4.24 Million |
immatics biotechnologies GmbH - Advanced Valuation Insights
This section examines the relationship between immatics biotechnologies GmbH's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 36.5% |
| Total Assets | $696.15 Million |
| Market Capitalization | $5.77 USD |
Valuation Analysis
Below Book Valuation: The market values immatics biotechnologies GmbH's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: immatics biotechnologies GmbH's assets grew by 36.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for immatics biotechnologies GmbH (2018–2024)
The table below shows the annual total assets of immatics biotechnologies GmbH from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $696.15 Million | +36.51% |
| 2023-12-31 | $509.96 Million | +25.05% |
| 2022-12-31 | $407.82 Million | +133.51% |
| 2021-12-31 | $174.65 Million | -31.42% |
| 2020-12-31 | $254.65 Million | +89.64% |
| 2019-12-31 | $134.28 Million | +118.98% |
| 2018-12-31 | $61.32 Million | -- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more